These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 37766132)

  • 1. Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis.
    Widhani A; Hasibuan AS; Rismawati R; Maria S; Koesnoe S; Hermanadi MI; Ophinni Y; Yamada C; Harimurti K; Sari ANL; Yunihastuti E; Djauzi S
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis.
    Li Z; Liu S; Li F; Li Y; Li Y; Peng P; Li S; He L; Liu T
    Front Immunol; 2022; 13():965971. PubMed ID: 36177017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis.
    Yin J; Chen Y; Li Y; Wang C; Zhang X
    Int J Infect Dis; 2022 Nov; 124():212-223. PubMed ID: 36241168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis.
    Du Y; Chen L; Shi Y
    Front Public Health; 2022; 10():829176. PubMed ID: 35493393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.
    Boekel L; Steenhuis M; Hooijberg F; Besten YR; van Kempen ZLE; Kummer LY; van Dam KPJ; Stalman EW; Vogelzang EH; Cristianawati O; Keijzer S; Vidarsson G; Voskuyl AE; Wieske L; Eftimov F; van Vollenhoven R; Kuijpers TW; van Ham SM; Tas SW; Killestein J; Boers M; Nurmohamed MT; Rispens T; Wolbink G
    Lancet Rheumatol; 2021 Nov; 3(11):e778-e788. PubMed ID: 34396154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.
    Ferri C; Ursini F; Gragnani L; Raimondo V; Giuggioli D; Foti R; Caminiti M; Olivo D; Cuomo G; Visentini M; Cacciapaglia F; Pellegrini R; Pigatto E; Urraro T; Naclerio C; Tavoni A; Puccetti L; Varcasia G; Cavazzana I; L'Andolina M; Ruscitti P; Vadacca M; Gigliotti P; La Gualana F; Cozzi F; Spinella A; Visalli E; Dal Bosco Y; Amato G; Masini F; Pagano Mariano G; Brittelli R; Aiello V; Caminiti R; Scorpiniti D; Rechichi G; Ferrari T; Monti M; Elia G; Franceschini F; Meliconi R; Casato M; Iannone F; Giacomelli R; Fallahi P; Santini SA; Zignego AL; Antonelli A
    J Autoimmun; 2021 Dec; 125():102744. PubMed ID: 34781162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
    Sharif N; Alzahrani KJ; Ahmed SN; Dey SK
    Front Immunol; 2021; 12():714170. PubMed ID: 34707602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
    Yuan P; Ai P; Liu Y; Ai Z; Wang Y; Cao W; Xia X; Zheng JC
    medRxiv; 2020 Nov; ():. PubMed ID: 33173896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
    Omma A; Batirel A; Aydin M; Yilmaz Karadag F; Erden A; Kucuksahin O; Armagan B; Güven SC; Karakas O; Gokdemir S; Altunal LN; Buber AA; Gemcioglu E; Zengin O; Inan O; Sahiner ES; Korukluoglu G; Sezer Z; Ozdarendeli A; Kara A; Ates I
    Hum Vaccin Immunother; 2022 Nov; 18(6):2122503. PubMed ID: 36315843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort.
    Zamani B; Moradi Hasan-Abad A; Piroozmand A; Dehghani M; Arfaatabar M; Motedayyen H
    Immun Inflamm Dis; 2023 May; 11(5):e858. PubMed ID: 37249277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Efficacy, and Immunogenicity of Varying Types of COVID-19 Vaccines in Children Younger Than 18 Years: An Update of Systematic Review and Meta-Analysis.
    Tian Y; Chen L; Shi Y
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Safety of the COVID-19 Vaccines Compared With Control in Healthy Adults: A Qualitative and Systematic Review.
    Lau O; Vadlamudi NK
    Value Health; 2022 May; 25(5):717-730. PubMed ID: 35500945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
    Fadlyana E; Rusmil K; Tarigan R; Rahmadi AR; Prodjosoewojo S; Sofiatin Y; Khrisna CV; Sari RM; Setyaningsih L; Surachman F; Bachtiar NS; Sukandar H; Megantara I; Murad C; Pangesti KNA; Setiawaty V; Sudigdoadi S; Hu Y; Gao Q; Kartasasmita CB
    Vaccine; 2021 Oct; 39(44):6520-6528. PubMed ID: 34620531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of COVID-19 mRNA vaccines in hemodialysis patients: Systematic review and meta-analysis.
    Falahi S; Sayyadi H; Kenarkoohi A
    Health Sci Rep; 2022 Nov; 5(6):e874. PubMed ID: 36210877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials.
    Moa AM; Chughtai AA; Muscatello DJ; Turner RM; MacIntyre CR
    Vaccine; 2016 Jul; 34(35):4092-4102. PubMed ID: 27381642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
    Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.